Skip to main content
. Author manuscript; available in PMC: 2017 Apr 28.
Published in final edited form as: Arthritis Care Res (Hoboken). 2013 Oct;65(10):1551–1563. doi: 10.1002/acr.22087

Figure 2.

Figure 2

Treatment pathways for patients without active systemic features and with varying degrees of synovitis. The Task Force Panel was asked to rate the appropriateness of therapies based on the total number of active joints (≤4 or >4). Children may qualify for >1 pathway, in which case it is left to the provider's discretion to choose the path they feel is most appropriate based upon specific patient characteristics and/or patient and family preferences. Steps in the progression of therapy can be additive or sequential, except that therapies with a biologic agent are sequential (combination therapy with a biologic agent is not endorsed). AJC = active joint count; MTX = methotrexate; NSAID = nonsteroidal antiinflammatory drug; IV = intravenous; TNF-α = tumor necrosis factor α.